From Promise to Proof
Join us in our travel back to the beginnings of what is clinically proven now: HighVolumeHDF.
“Secrets, especially with cooking, are best shared so that the cuisine lives on” – Chef Bo Songvisava. The “So You Think You Can Cook? WOK IT!” cooking competition created a brand new dialysis recipe book for your patients to download now.
Fresenius Medical Care Malaysia will be present at the 29th Annual Congress of Malaysian Society of Nephrology and is looking forward to introducing you to our new Online Renal Platform. Visit us and discover how we can further support you.
Few studies have compared resource consumption and costs associated with haemodialysis (HD) and peritoneal dialysis (PD) access. Here we report results from a retrospective analysis titled: Cost analysis of haemodialysis and peritoneal dialysis access in incident dialysis patients1 comparing these treatments in the first year of therapy that may have important implications for policymakers.
High-Volume HDF improves patient survival
The Catalonian Online Haemodiafiltration Survival Study (ESHOL) published in February 2013 confirms Fresenius Medical Care’s conviction that every patient should be given the chance to benefit from haemodiafiltration (HDF) therapy with high volumes of substitution fluid (HighVolumeHDF). The primary outcome of the study was that HighVolumeHDF therapy significantly improves patient survival compared with conventional dialysis treatment. At this year’s ERA-EDTA Congress, HighVolumeHDF was the main focus of Fresenius Medical Care’s activities.